Accelrys Announces DS Modeling 1.2 – SBD: Structure-Based Design Tools for Drug Discovery
Accelrys Inc., a wholly owned subsidiary of Pharmacopeia, Inc. (NASDAQ: PCOP), today announced the release of its structure-based design tools for the Discovery Studio(R) family of products. DS Modeling 1.2 - SBD is a client-server environment for in silico drug design on Windows(R)-based personal computers.
Accelrys Announces MS Modeling 3.0
New Materials Studio Tools for Property Prediction and Crystallization Modeling
Accelrys Announces Accord Enterprise Informatics 5.3 and DS Accord for Excel Enterprise
Accelrys, a wholly owned subsidiary of Pharmacopeia, Inc. (NASDAQ: PCOP), today announced the release of its latest solutions for chemical and biological information management: Accord Enterprise Informatics and DS Accord for Excel Enterprise.
Agilent Technologies to Integrate Its HPLC and ChemStation Solutions with Advanced Chemistry Development’s AutoChrom and ChromGenius Software
PALO ALTO, CA and Toronto, August 20, 2003 - Agilent Technologies Inc. (NYSE: A) and Advanced Chemistry Development, Inc., (ACD/Labs) today announced an agreement to develop and market the integration of ACD/Labs' AutoChrom and ChromGenius software with the Agilent ChemStation software and 1100 Series HPLC systems.
IAL Biolytix and Innaphase Corporation Sign Agreement to Implement the Watson™ Laboratory Information Management System
InnaPhase Corporation, the world’s largest provider of Laboratory Information Management Systems (LIMS) for the pharmaceutical industry, today announced that IAL Biolytix, has signed a license agreement to implement InnaPhase’s WatsonTM Laboratory Information Management System for their Monmouth Junction, New Jersey facility in the United States.
IBM InsightLink Brings Critical Research Thinking Online
New Productivity Tool for Capturing and Sharing Ideas, Notes and Annotations
FDA Announces New Progress Toward “21st Century” Regulation of Pharmaceutical Manufacturing
On the first anniversary of the launch of its initiative, the Food and Drug Administration (FDA) today outlined new steps in its strategic initiative to modernize the regulation of pharmaceutical manufacturing and product quality.


